Blog
About
PARINC.COM
MENU
CHECK OUT
Login
SEARCH
1-800-331-8378
Blog
About
PARINC.COM
Search
1.800.331.8378
Practice
,
Research
New Study Will Test Effectiveness of Alzheimer’s Prevention Drug
July 10, 2012
In the search for more effective treatments for Alzheimer’s disease, a new clinical trial will test whether a prevention drug has any effect on patients who are genetically predisposed to develop the disease, but
who don’t yet exhibit symptoms. In the study, scientists are focusing on members of a large, extended family in Medellín, Colombia, some of whom have a specific genetic mutation that is linked to early-onset dementia. The trial will be “the first to focus on people who are cognitively normal but at very high risk for Alzheimer’s disease,” said Dr. Francis S. Collins, director of the National Institutes of Health (NIH), in a May 15 interview with the
New York Times
.
Members of the Colombian family who have the genetic mutation begin showing cognitive impairment around age 45 and develop full dementia by age 51. Three hundred family members, some as young as age 30, will participate in the initial trial.
The five-year study is a collaboration between the
NIH
, the nonprofit
Banner Alzheimer’s Institute
,
Genentech
(maker of the drug crenezumab, which will be used in the trial), and the University of Antioquia in Medellín. The trial will help to test the amyloid theory of Alzheimer’s, which holds that the disease is caused by a steady buildup of the beta amyloid protein. Some results of the trial—specifically those that address whether the drug can delay memory decline—may be available in as little as two years, according to study leader
Ken Kosik
, codirector of the Neuroscience Research Institute at University of California, Santa Barbara.
Although only a small percentage of people with Alzheimer’s have the genetic early-onset form, researchers expect the trial to yield information that will help millions people who are affected more common forms of the disease. “It offers a tremendous opportunity for us to answer a large number of questions, while at the same time offering these people some significant clinical help that otherwise they never would have had,” said Dr. Steven T. DeKosky, an Alzheimer’s researcher from the University of Virginia School of Medicine, in the
New York Times
article.
To learn more about this and other ongoing studies of Alzheimer’s disease, visit the NIH’s
National Institute on Aging
Web site.
Categories
About PAR (77)
Advocacy (24)
Books (8)
Community PARtners (38)
Conference (45)
Contest (3)
Discounts (13)
General (14)
Meet the Author (24)
Movies (1)
New Products (113)
PAR Author (65)
PAR Staff (42)
Practice (118)
Products (131)
Research (152)
Training (26)
Training Portal (2)
Uncategorized (7)
Webinar (16)
White Paper (4)
Archives
2021
January (2)
2020
January (4)
February (4)
March (5)
April (2)
May (3)
June (5)
July (4)
August (4)
September (5)
October (5)
November (5)
December (5)
2019
January (4)
February (4)
March (4)
April (5)
May (4)
June (4)
July (5)
August (4)
September (4)
October (5)
November (4)
December (5)
2018
January (5)
February (4)
March (4)
April (4)
May (5)
June (4)
July (5)
August (4)
September (4)
October (5)
November (3)
December (4)
2017
January (5)
February (4)
March (4)
April (4)
May (5)
June (4)
July (4)
August (4)
September (4)
October (5)
November (4)
December (3)
2016
January (4)
February (4)
March (5)
April (4)
May (5)
June (4)
July (3)
August (5)
September (6)
October (4)
November (5)
December (4)
2015
January (7)
February (4)
March (6)
April (4)
May (4)
June (5)
July (4)
August (4)
September (5)
October (4)
November (4)
December (5)
2014
January (4)
February (4)
March (4)
April (5)
May (4)
June (4)
July (5)
August (4)
September (4)
October (5)
November (4)
December (5)
2013
January (5)
February (4)
March (4)
April (5)
May (4)
June (4)
July (5)
August (4)
September (4)
October (5)
November (5)
December (5)
2012
January (5)
February (4)
March (5)
April (5)
May (5)
June (4)
July (6)
August (4)
September (5)
October (6)
November (4)
December (4)
2011
January (4)
February (4)
March (5)
April (3)
May (6)
June (5)
July (5)
August (5)
September (4)
October (5)
November (5)
December (4)
2010
May (4)
June (3)
July (5)
August (4)
September (2)
October (3)
November (3)
December (3)
Contact PAR
Customer Support:
1.800.331.8378
Tech Support:
1.800.899.8378
Email:
cs@parinc.com
Website:
www.parinc.com
Recent Posts
Dream bigger. Leave the norm.
Don’t let old forms clutter your office!
2020: An Assessment Round Up!
New Research on the ChAMP
PAR Pays It Forward!
Read More »
Tags
online assessment
AAB
APA
assessment
authors
autism
BRIEF
BRIEF2
career
career counseling
career interest inventory
ChAMP
children
Community PARtners
concussion
Customer Service
customer support
depression
executive function
FAR
feifer
free training
intelligence
John Holland
learning disabilities
memory
mental health
NASP
neuropsychology
online assessment
PAI
PAR
PAR staff
PARiConnect
personality
post-traumatic stress disorder
Psychology
ptsd
reading
research
retirement
SDS
Self-Directed Search
suicide
tbi
training
training portal
trauma
United Way
webinar